tiprankstipranks
Percheron Therapeutics Advances with Strong Funding and Trials
Company Announcements

Percheron Therapeutics Advances with Strong Funding and Trials

Percheron Therapeutics (AU:PER) has released an update.

Pick the best stocks and maximize your portfolio:

Percheron Therapeutics has made significant progress in the past quarter, with its drug Avicursen showing promising preclinical results in reducing seizure frequency in autoimmune epilepsy. The company has also completed a crucial nine-month animal toxicology study with no unexpected findings and secured $13 million through an oversubscribed institutional placement, ensuring funding into 2026. Investors are eagerly anticipating the initial data readout from a Phase IIb trial of Avicursen in Duchenne muscular dystrophy, expected in December 2024.

For further insights into AU:PER stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Australian Auto-Generated NewsdeskPercheron Therapeutics Announces Cessation of Securities
TipRanks Australian Auto-Generated NewsdeskPercheron Therapeutics: Shareholding Increase Sparks Investor Interest
TipRanks Australian Auto-Generated NewsdeskPercheron Therapeutics Halts Avicursen Trial Amid Disappointing Results
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App